Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder.
Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse reaction to neuroleptics, which is characterized by hyperthermia, extrapyramidal symptoms, altered consciousness and autonomic dysfunction. Although NMS is most commonly induced by the high-potency neuroleptics, its development has also been associated with the use of non-neuroleptic agents that block central dopamine pathways. A 68-year-old man with generalized anxiety disorder and depressive symptoms presented at the emergency department (ED) with high fever, tremor, muscle rigidity, rhabdomyolysis and altered mental status. NMS was considered to have been caused by the recent addition and subsequent dose increase in his treatment regimen of venlafaxine, a serotonin norepinephrine reuptake inhibitor. He was successfully treated with bromocriptine, lorazepam, and fluid hydration in the ED and intensive care unit.
Lu
Tsung-Chien
TC
Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.
Chu
Pei-Lun
PL
Wu
Chi-Shin
CS
Tsai
Kuang-Chau
KC
Chen
Wen-Jone
WJ
D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy*; D003511:Cyclohexanols / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride